KALA BIO (KALA) investor relations material

Company overview and business model

• Transitioning from biologics R&D to an AI platform-as-a-service model for biotech and pharma clients, leveraging proprietary datasets and IP from discontinued clinical programs.

• Discontinued lead biologics program (KPI-012) after failed Phase 2b trial; now focused on monetizing legacy assets and developing the Researgency AI platform under exclusive license.

• Researgency platform aims to provide secure, on-premises AI infrastructure for biotech research, targeting mid-size biotech, CROs, and pharma companies.

• Strategy includes out-licensing or selling biologics assets and using internal clinical datasets to validate the AI platform.

Financial performance and metrics

• Reported net loss attributable to common stockholders: $(26,980) thousand for 2025 and $(38,511) thousand for 2024.

• Basic and diluted net loss per share: $(165.56) for 2025 and $(507.25) for 2024, retroactively adjusted for a 1-for-50 reverse stock split.

• Number of common shares outstanding post-split as of June 9, 2026: 18,589,787.

• Classified as a smaller reporting company, allowing for scaled disclosure and reduced reporting requirements.

Use of proceeds and capital allocation

• Proceeds from any securities sales will be used for general corporate purposes, including product development, manufacturing, sales, marketing, and working capital.

• Management retains broad discretion over allocation of net proceeds; may invest in short-term securities or reduce short-term debt.